Deal Announcements

Cequent Receives $6 Million Series A

Monday, December 18, 2006 8:30:00 AM PDT | VentureDeal Staff

CAMBRIDGE, MA  --  Cequent Pharmaceuticals today announced the closing of a $6 million series A round of financing.

The company licensed technology from the Beth Israel Deaconess Medical Center & Harvard Medical School which allows for RNAi-based treatments to be carried by bacteria into targeted areas deep within the human body, without surgery.

Cequent is in pre-clinical stage and is focusing its efforts on gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1